OrthoPediatrics Corp. appears in FDA records as the applicant for the Pediatric Nailing Platform | Femur, a Class II intramedullary fixation rod device regulated under 21 CFR 888.3020 with product code HSB. The FDA clearance letter for K261345 lists the applicant at 2850 Frontier Dr., Warsaw, Indiana, and names Jessica Powers as senior regulatory affairs specialist. The same device family was cleared earlier under K220679, whose clearance letter identifies the trade name Pediatric Nailing Platform | Femur and the same regulation and product code. The manufacturer’s product page describes the platform’s intended use in pediatric and small-stature adult patients for stabilization of femoral shaft fractures, subtrochanteric fractures, ipsilateral neck/shaft fractures and prophylactic nailing of impending pathologic fractures. [1][2][3][9]
Documented filing history
FDA’s 510(k) record for K261345 shows a Traditional submission received April 23, 2026, with a decision date of September 24, 2026 and decision code SESE, described as substantially equivalent. The clearance letter carries the same decision date and lists the device as dated and received August 28, 2026. The earlier K220679 clearance letter, dated July 20, 2022, covers the Pediatric Nailing Platform | Femur under the same regulation number and product code, with a submission prepared in March 2022. [1][2][6][9]
The linked collection for this company contains one 510(k) record, K261345, and its decision count is one SESE. That count reflects the records retrieved as of the snapshot date and is not a statement of total company filings, sales or portfolio breadth. [1]
Product scope as published
The manufacturer’s product page states that Pediatric Nailing Platform | Femur is designed for pediatric and small stature adult patients and lists indications covering femoral shaft fractures, subtrochanteric fractures, ipsilateral neck/shaft fractures and prophylactic nailing of impending pathologic fractures. The page also references surgical technique documents and patient charge sheets for Gen I stainless steel, Gen II stainless steel and Gen II cobalt chrome configurations, along with a small canal solutions sales aid. [3]
A surgical technique document for the platform lists acknowledgements from pediatric orthopedic surgeons at Miller Children’s and Women’s Hospital, Washington University in St. Louis School of Medicine, Geisinger Commonwealth School of Medicine and University of Utah. The document also carries trademark statements for several product names, including ApiFix, ArmorLink, Scwire and ShieldLoc, in specified jurisdictions. [4]
Company announcements and corporate record
An OrthoPediatrics news release dated October 27, 2026 announces FDA 510(k) clearance of the Pediatric Nailing Platform | Femur Retrograde Nail System and completion of first implantations, describing the addition as expanding options for pediatric femoral trauma and deformity correction. The release identifies OrthoPediatrics Corp. as a Nasdaq-listed company focused exclusively on pediatric orthopedics. [5]
The company’s 2025 annual report includes a CEO letter to shareholders signed by David R. Bailey, President and Chief Executive Officer, and a Form 10-K signature page dated March 4, 2026. These documents describe corporate leadership and reporting but do not establish ownership of any parent or brand beyond the named registrant. [7]
Identity and attribution
FDA records identify OrthoPediatrics Corp. as the applicant and correspondent for K261345, with the Warsaw, Indiana address listed as a filing address rather than a verified headquarters. The manufacturer’s product page and surgical technique document are published by OrthoPediatrics and describe the device’s stated indications and components; they are not independent clinical evidence. [1][2][3][4]
No parent company, brand ownership, customer list, certification or commercial availability beyond the cited filings and announcements is established in the available records. [1][5][7]
